Introduction
It has been shown that primary acute myeloid leukaemia (AML) blasts can be induced to differentiate into dendriticlike leukaemia cells (DLLC) by culture with certain cytokine combinations. These DLLC share many features in common with monocyte-derived dendritic cells (MDDC) in that they express the costimulatory molecules CD40, CD80 and CD86 and the dendritic cell-associated molecule CD83, [1] [2] [3] [4] [5] [6] [7] [8] [9] secrete the immunostimulatory cytokine IL-12 3 and are potent stimulators of allogeneic T lymphocytes in mixed leukaemia lymphocyte reactions (MLLR). [1] [2] [3] [4] [5] [6] 9 Importantly, it has been demonstrated that autologous cytotoxic T lymphocytes, capable of recognising and destroying unmodified leukaemia cells, can be generated by co-culturing T cells with autologous DLLC. 3, 4, 6 Based on this ability to present putative leukaemia-specific antigens to autologous T cells, DLLC might offer potential as vaccines for the treatment of AML.
There is a need for novel treatment strategies in AML, particularly in the elderly where current approaches aimed at erad-icating minimal residual disease (MRD) such as stem cell transplantation are not currently applicable due to unacceptably high levels of treatment morbidity and mortality. If proven to be effective at generating immunity in vivo DLLC vaccination may have a role in the eradication of MRD following prior chemotherapy-induced remission. However, based on in vitro studies of DLLC differentiation, in about 30-50% of AML patients DLLC vaccination would not be possible because the leukaemia cells are unable to differentiate. 2, 4, 6, 9 The factors important in preventing DLLC differentiation have not previously been identified. The AML French-AmericanBritish classification (FAB) subtype does not appear to predict DLLC differentiation potential as leukaemia cells from all FAB subtypes have been shown to undergo DLLC differentiation. [1] [2] [3] [4] [5] [6] [7] [8] [9] A more significant determinant may be the cytogenetic/ molecular rearrangement underlying the individual cases of AML. Several lines of evidence point towards a common theme in the molecular pathogenesis of AML, namely that the end result of the majority of the commonest chromosomal translocations is the transcriptional repression of genes involved in haematopoietic differentiation. 10 The histone deacetylase inhibitor, trichostatin (TSA), and the DNA demethylase, azacytidine (AZA), are able to induce differentiation in myeloid leukaemic cells by relieving transcriptional repression through altering histone acetylation 11, 12 and DNA methylation 13, 14 status, respectively. A different class of differentiating agent, bryostatin (BRYO) exerts its action by interfering with protein kinase C activity. BRYO has been shown to be able to induce monocytic differentiation in myeloid leukaemia cells. 15, 16 In this study we have sought to define the features that represent successful DLLC differentiation and determine which clinical characteristics are important in predicting the differentiation potential of individual AML cases. For those AML cases shown to be resistant to DLLC differentiation the differentiating agents TSA, AZA and BRYO were used, in combination with cytokines, in an attempt to overcome the block to differentiation.
Materials and methods

Patient samples
Blood and bone marrow samples were taken from patients with AML at presentation or relapse following written informed consent using a study protocol that had received prior approval from the local Research Ethics Committee. Mononuclear cells were separated by gradient centrifugation over lymphocyte separation medium (Nycomed, Amersham, UK). Purity of leukaemia blasts in mononuclear cell preparations was greater then 90% in all cases tested. Diagnosis was established by cytological criteria based on the FAB classification. Table 1A AML cases in which the leukaemia cells were permissive to cytokine-induced differentiation to dendritic-like cells De novo/  AML  % cells expressing cell surface markers  Karyotype  (years)  Secondary subtype  CD14  CD40  CD80  CD86  HLA II   UPN1  82  de novo  M0  13  1  1  2  97  46,XX  UPN3  26  de novo  M1  0  36  0  2  99  47XY,+19  UPN4  64  de novo  M 1  0  0  0  1  8  45XY  UPN6  73  de novo  M 1  1  3  3  0  8 1  Fail  UPN9  11  de novo  M1  ND  1  15  25  96  47XY,+8  UPN11  81  de novo  M2  11  15  1  11  20  46XX  UPN14  78  de novo  M 2  1  2  1  2  9 Karyotypes were defined according to criteria of the International System for Human Cytogenetic nomenclature. Leukaemia cells were cryopreserved in RPMI 1640 medium with 10% fetal bovine serum (FCS) and 10% DMSO for later use.
UPN Age
Cytokine-induced differentiation of primary leukaemia cells
Leukaemia cells were cultured in six-well plates at 10 6 cells/ml in RPMI 1640 containing 5% heat inactivated human AB serum, l-glutamine (2 mmol/l) and penicillin/streptomycin (50 U/ml) (GIBCO BRL, Paisley, UK) to which was added GMLeukemia CSF 200 ng/ml (Schering-Plough, Welwyn Garden City, UK) and IL-4 20 ng/ml (R&D Systems, Abingdon, UK). The cells were incubated for 96 h at 37°C, 5% CO 2 . Medium was then replaced with fresh cRPMI supplemented with GM-CSF 200 ng/ml and either CD40 ligand (CD40L) 1 g/ml (Alexis Corporation, Nottingham, UK) or TNF␣ 15 ng/ml (R&D, Abingdon, UK), given to induce DLLC maturation. Initial experiments were performed with CD40L, however, following a comparative analysis in which CD40L and TNF␣ were found to be equivalent in their ability to induce DLLC maturation (data not shown) TNF␣ was used in all subsequent experiments. Following a further 72 h culture cells were harvested and used either for flow cytometric analysis or as stimulators in allogeneic MLLR. Tissue culture supernatants from cases where CD40L was given as the maturational agent were collected and stored at −20°C prior to analysis of IL-12(p70) production by cultured leukaemia cells.
Flow cytometric analysis
Cells were incubated with 0.5% human normal immunoglobulin solution (Scottish National Blood Transfusion Service, Edinburgh, UK) for 30 min at 4°C to prevent non-specific binding. 2 × 10 5 cells were either single stained with monoclonal antibodies (mAb) directed against CD14, CD54, CD80, CD86, CD95, HLA class II (fluorescein-conjugated) (all Serotec, Oxford, UK) or dual stained with mAb directed against CD40 (fluorescein-conjugated) (Serotec) and CD83 (phycoerythrin-conjugated) (Beckman Coulter, High Wycombe, UK) for 30 min at 4°C. Cells were then resuspended in 100 l phosphate-buffered saline (PBS) containing 2 g/ml propidium iodide (Bender MedSystems, Middlesex, UK). After 5 min incubation analysis was performed on a FACSCalibur (Becton Dickinson, USA). Viable cells were defined with a forward scatter (FS)/PI gate. 
Determination of origin of DLLC by fluorescence in situ hybridization (FISH)
In order to establish whether DLLC were indeed derived from the leukaemic clone FISH analysis for a specific leukaemiaassociated chromosomal rearrangement, inv (16) , was performed using the leukaemia cells from one potentially informative AML case (UPN 35). DLLC were generated by culture of leukaemia cells with cytokines as described above. In order to obtain a pure population of dendritic-like cells immunomagnetic selection of CD83-positive cells was performed. 5 × 10 6 cells were first labelled with 20 l of anti-CD83 (phycoerythrin-conjugated) mAb for 15 min. The cells were then incubated with 20 l of anti-PE microbeads (Miltenyi Biotec, Surrey, UK) for 30 min at room temperature. The cell suspension was then run through a miniMACS column (Miltenyi Biotec). The positive fraction was recovered and used to make cytospin slide preparations. Hybridisation with a CBF␤ dual-colour probe (Vysis (UK) Ltd, Surrey, UK) was performed according to the manufacturer's instructions. The slides were counterstained with 4Ј,6-diamidino-2-phenylindole-dihydrochloride (Sigma-Aldrich, Gillingham, UK). Two hundred interphase nuclei were examined in order to quantify the percentage showing loss of the normal co-localisation signal from the two CBF␤ probes, which characterises the inv(16) rearrangement.
Detection of cytokine production by ELISA
The production of IL12(p70) was measured by ELISA using a commercially available kit (Becton Dickinson, Oxford, UK).
Addition of differentiating agents to the cytokine regimen in an attempt to overcome differentiation resistance
Nine cases that had been shown to be resistant to cytokineinduced DLLC differentiation were selected for further study based on the availability of multiple samples. Leukaemia cells were cultured under identical conditions except that for the first 96 h of the culture period differentiating agents TSA 100 ng/ml (CN Biosciences, Nottingham, UK) in combination with AZA 1 M (Sigma-Aldrich) or BRYO 10 nM alone (ICN Biochemicals, Basingstoke, UK) were used in addition to the standard cytokine regimen. The doses of these agents were selec-
Figure 2
Immunophenotypic characteristics of leukaemia cells cases following attempted cytokine-induced differentiation in differentiationresistant AML cases. There is a low proportion (Ͻ5%) of cells showing dual expression of CD40 and CD83 on the dot plot analysis and a lack of CD80 and CD86 expression on the histogram analyses. Experiments were performed using leukaemia cells from AML cases (a) UPN2, (b) UPN5 and (c) UPN20.
Leukemia ted by assessing the decrease in cell viability of primary leukaemia cells following culture at increasing concentrations of differentiating agents. The highest concentration at which cell viability remained greater than 50% was selected for use in differentiation experiments. Following culture with differentiating agents the medium was replaced with fresh cRPMI containing GM-CSF 200 ng/ml and TNF␣ 15 ng/ml. Following a further 72 h culture cells were harvested and used either for flow cytometric analysis or as stimulators in allogeneic MLLR.
Allogeneic MLLR
Responder T cells were isolated from mononuclear cells obtained from healthy donors by discarding adherent cells following overnight plastic adherence. Stimulator cells were treated with 25 g/ml mitomycin C (Sigma-Aldrich) for 2 h and then added in graded doses to 1 × 10 5 allogeneic T cells in 96-well U-bottomed tissue culture plates in RPMI 1640 containing 5% heat-inactivated human ABS. Cell proliferation was quantified by incubating the cells for the last 18 h of 5 days culture with 1 Ci thymidine (ICN Biochemicals). Results presented are the mean cpm obtained from triplicate cultures.
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Statistical analyses
Results were analysed by means of standard equations for the mean, s.d. and Student's paired t-test.
Results
Costimulatory molecule and HLA II expression by leukemia cells prior to differentiation
Expression of costimulatory molecules CD40 and CD86 (Ͼ20% cells expressing cell surface marker) was present in a minority of cases prior to differentiation (six and nine of 42 AML cases, respectively) ( Table 1) . No AML cases had significant levels of expression of CD80. CD14, a marker of monocytic differentiation, was expressed in 5/42 cases all of which were of FAB subtypes M4 or M5. HLA II expression was present in 33 cases. No appreciable levels of expression of the dendritic cell markers CD1a and CD83 were identified on the leukemia cells from AML cases prior to differentiation.
Resistance of primary AML blasts to cytokine-induced differentiation to DLLC is associated with poor risk karyotypic features
Leukaemia cells were deemed to have undergone differentiation to DLLC based on the acquisition of characteristic dendritic cell-like morphology, expression of costimulatory molecules CD40, CD80 and CD86 and the appearance of a dual CD40/83 expressing population (Figure 1 ). The immunophenotypic criteria used to separate DLLC permissive from resistant cases were that if Ͼ20% of leukemia cell population showed expression of CD40 in combination with Ͼ20% cells showing expression of either CD80 and/or CD86 then DLLC differentiation was deemed to have taken place. Leukemia cells from AML cases that failed to undergo differentiation to DLLC did not show significant levels of expression of CD80 or CD86 (Figure 2) . A proportion of the resistant cases showed weak expression of CD40 following culture but this was not associated with the appearance of a CD40/83 dual-expressing population. There was an increase of CD54 expression following leukaemia cell culture in the majority of AML cases regardless of whether they had undergone DLLC differentiation, but mean fluorescence intensity was higher in leukaemia cells that had become DLLC (data not shown). HLA class II expression was upregulated in all DLLC and in 14/16 of the differentiation-resistant cases.
Review of the clinical features of AML cases that were permissive and those that were resistant to DLLC differentiation suggested an association between differentiation resistance and poor risk karyotype. Fifty per cent of AML cases that were resistant to DLLC differentiation had poor risk karyotypic features compared with none in the differentiation permissive cases. Three of 22 of the differentiation permissive cases were associated with favourable karyotypes (Table 1) .
DLLC were shown to be derived from the leukaemic clone
FISH analysis of CD83-positive DLLC, generated by the culture of leukaemia cells from AML case UPN 35 with cytokines GM-CSF, IL-4 and TNF-␣ followed by immunomagnetic 
FAB subtype influences the maturational response to CD40L as measured by IL-12 production
Following maturation with CD40L IL-12(p70) production of Ͼ50 pg/ml by the cultured leukaemia cells was found in five of the 16 AML cases that were considered to have undergone DLLC differentiation (Figure 4) . These five were all derived from AML subtypes M4 or M5, ie having a monocytic component. IL-12(p70) production by leukaemia cells following cul-
Figure 4
A comparison of IL-12(p70) production by DLLC and differentiation-resistant leukaemia cells after culture of leukaemia cells with cytokines GM-CSF, IL-4 for 96 h followed by 72 h culture with GM-CSF and CD40 ligand. ture with the cytokine regimen in the differentiation resistant AML cases was consistently Ͻ50 pg/ml. 
DLLC are potent stimulators of allogeneic T cells in MLLR whereas differentiation-resistant leukaemia cells are only weakly immunostimulatory
DLLC were potent stimulators of allogeneic T lymphocyte proliferation in MLLR. In comparison, freshly thawed leukaemia cells derived from the same AML cases were poor stimulators of allogeneic lymphocytes ( Figure 5 ). Leukaemia cells from differentiation-resistant AML cases that were cultured with the cytokines in an attempt to induce differentiation were found to be only weakly immunostimulatory ( Figure 6 ).
Bryostatin-1 in combination with cytokines could overcome the block to DLLC differentiation in a proportion of the resistant cases
TSA and AZA were found to be ineffective at overcoming differentiation resistance. When given at the highest dose above which there was excessive loss in cell viability they failed to induce any upregulation in costimulatory molecule or CD83 expression in differentiation-resistant leukaemia cells (data not shown). In contrast, BRYO was effective at permitting differentiation to DLLC in six of nine resistant cases (Table 2) . Within 24 h of BRYO being added to the cultures the majority of leukaemia cells become adherent. In the cases that subsequently went on to become DLLC the adherent cells acquired morphological features characteristic of dendritic cells (Figure 7) . In contrast to MDDC and DLLC generated without BRYO that become loosely adherent as they mature, the BRYO-treated cells remained adherent through out the culture period. However, flow cytometric analysis showed the typical DLLC immunophenotypic profile of increased CD80 and CD86 expression and a dual-positive CD40/CD83 population ( Figure 8 ). The remaining cases that failed to show complete conversion to DLLC did have an increase in CD40 expression in comparison with cells cultured with cytokines alone.
Figure 8
Immunophenotypic characteristics of leukaemia cells following culture with bryostatin-1 in combination with cytokines. Leukaemia cells were cultured for 96 h with cytokines GM-CSF and IL-4 in combination with bryostatin-1, followed by a further 72 h culture with GM-CSF and TNF␣ alone. On the dot plot analysis there is a significant population of CD40/CD83 dual-expressing cells. This is accompanied by upregulation of CD80 and CD86 expression as shown on the histogram plots. Experiments were performed using leukaemia cells from AML cases (a) UPN2, (b) UPN5 and (c) UPN20.
Bryostatin-1 in combination with cytokines increases the allostimulatory properties of differentiationresistant leukaemia cells in comparison with those cultured with cytokine alone
Leukaemia cells from differentiation-resistant cases that had been allowed to undergo DLLC differentiation by the addition of BRYO to the standard cytokine regimen were found to be effective at stimulating allogeneic T lymphocyte proliferation in MLLR whereas leukaemia cells from the same cases cultured in parallel, but without additional BRYO, were only weakly immunostimulatory (Figure 9 ). BRYO-treated leukaemia cells produce comparable amounts of T cell proliferation in MLLR as DLLC derived from differentiation-permissive AML cases.
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Discussion
In this study we have sought to identify the immunophenotypic and functional characteristics that define successful DLLC differentiation from primary AML blasts. Following attempted cytokine-induced differentiation, leukaemia cells from cases that successfully underwent DLLC transformation were characterised by the appearance of a dual-expressing CD40/CD83-positive population in combination with expression of CD80 and/or CD86. Functional analysis of DLLC showed that they were potent stimulators of allogeneic T cells in MLLR. Leukaemia cells derived from differentiationresistant cases, following attempted cytokine-induced differentiation, failed to acquire the immunophenotypic characteristics of DLLC and were found to be only weakly immunostimulatory in allogeneic MLLR.
Figure 9
Allogeneic mixed leukaemia lymphocyte reactions. Responders: allogeneic peripheral blood lymphocytes. Stimulators: leukaemic cells cultured with GM-CSF/IL4 with or without bryostatin-1 from AML cases (a) UPN20 and (b) UPN26 that had previously been shown to be resistant to DLLC differentiation. Results represent the mean ± s.d. of triplicate cultures.
A comparison was made between the clinical features of AML cases that were considered to be either differentiationpermissive or -resistant. In contrast to AML cases that were able to undergo DLLC transformation there was a high incidence of poor risk karyotypic features among the differentiation-resistant cases. It appears, therefore, that chromosomal and molecular rearrangements that are known to predict for poor treatment outcomes in AML are also important in predicting DLLC differential potential. The rationale for using the histone deacetylase inhibitor TSA and DNA demethylase AZA in an attempt to overcome differentiation resistance was based on evidence demonstrating that changes in histone acetylation and DNA methylation status are important in mediating transcriptional repression in AML. There may be a variety of possible reasons why this approach was not successful. AML cases possessing complex karyotypic alterations will have multiple molecular rearrangements, many or all of which might contribute to the differentiation block. In addition, the molecular consequences of these poor risk cytogenetic/molecular rearrangements may be to repress haematopoietic gene transcription by mechanisms unrelated to changes in histone acetylation or DNA methylation status. BRYO-1 promotes differentiation by interfering with protein kinase C activity. 16 It has been shown to be effective at inhibiting the clonogenicity of myeloid leukaemia cells. 17 The success of BRYO in allowing differentiation to DLLC in resistant AML cases might be a consequence of its inhibitory effects on cell cycle progression. Cell cycle arrest in these differentiation-resistant cases may be sufficient to permit the cell to respond positively to differentiation signals induced by cytokines, thereby allowing DLLC differentiation to proceed. Whether this truly represents the action of BRYO is uncertain and therefore future studies at our institution will be focused on attempting to elucidate the exact mechanism by which BRYO exerts its differentiating effect on leukemia cells for the purpose of finding new approaches to restoring differentiation potential in resistant leukemia cells. By using agents such as BRYO in combination with cytokines it should be possible to increase the proportion of AML cases that are capable of undergoing DLLC differentiation. This is of particular significance because it would appear that the patients most likely to be excluded from receiving DLLC vaccination are those with karyotypically poor risk AML. However, it is these patients who are most in need of alternative therapeutic approaches, as their outlook with conventional combination chemotherapy regimens is extremely poor. In the UK MRC X trial the 5 year survival rate for patients with karyotypically poor risk AML was only 17%. 18 Whereas FAB subtype was not considered to be an important factor in predicting DLLC differentiation potential it did appear to influence subsequent DLLC maturation. Only AML cases of FAB subtypes M4/M5 produced appreciable levels of IL-12(p70) following maturation with CD40L. Whether this represents a true inability of DLLC generated from AML cases of FAB subtypes other than M4 and M5 to produce IL-12 or whether additional maturational stimuli are required to fully mature DLLC derived from these cases remains to be determined. This may be important if DLLC are to be used in an attempt to generate immunity to leukaemia in vivo. Data from studies examining maturation of MDDC suggest that IL-12 production by MDDC plays a crucial role in directing T cells towards a Th1 cytokine phenotype. 19, 20 Th1-type responses are believed to be more relevant in the development of effective anti-tumour immunity. 21 It will be important, therefore, to characterise the nature of any in vivo T cell responses following DLLC vaccination in order to determine whether these are dependent on the maturational status of the DLLC. These issues will need to be addressed by performing in vivo studies of DLLC vaccination. This may not be possible in a murine setting as we have found in one murine AML model that the leukaemia cells were resistant to cytokineinduced DLLC differentiation (data not shown). It might be necessary therefore to perform clinical trials as the next step in the development of DLLC vaccination as immunotherapy for AML.
